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Carboxypeptidase O (CPO) is a membrane-bound peptidase that cleaves acidic and polar
C-terminal amino acids of peptides; however, its biological function remains unknown. CPO is
strongly expressed in the small intestine, where it has been proposed to participate in digestion
events at the brush border by extracellular cleavage of dietary peptides. At the subcellular level,
CPO is anchored to the inner leaflet of the endoplasmic reticulum (ER) membrane, where it has
been shown to associate with lipid droplets (LDs). The ER membrane also represents the site of
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chylomicron formation, a process that shares many similarities with that of LDs biogenesis. We
sought to investigate a potential role of CPO in LD and chylomicron formation. Using a stablyexpressing human colon carcinoma (Caco-2) cell model, we evaluated CPO association with
LDs and apoB, a chylomicron biomarker, by immunofluorescence microscopy. The association
of CPO with LDs was dependent on the time elapsed post-feeding (ANOVA, p < 0.05), and was
lowest at 6 h (17.9%), reaching a maximum at 12 h (29.8%) and later slightly decreasing at 24 h
(26.3%). Our results indicate that CPO associated with apoB, further showing a similar
association pattern as that of LDs at the three time points. However, we express a limited level of
confidence in these results since the immunocytochemistry images presumably suggest lower
association levels than those reported in the quantification data. Overall, our findings strengthen
the hypothesis that CPO plays an intracellular role in the formation of lipid droplets in
enterocytes.
To better understand the potential biological role of CPO, we performed an in-depth
analysis of data from several gene expression databases and platforms. RNA-Seq and microarray
expression data showed high expression in the ileum epithelium and mucosa. Modulation of
CPO expression, which was mainly characterized by downregulation in the ileum, was found in
ulcerative colitis and Crohn’s disease, with the latter showing stronger modulation. RNA-Seq
data also showed prominent expression in Peyer’s patches and basophils, which suggested a
promising role of CPO in immunity.
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CHAPTER 1

INTRODUCTION

1. Carboxypeptidases
Carboxypeptidases are enzymes characterized for cleaving the C-terminal amino acid of
peptides and proteins and are known to have diverse physiological functions such as cell
signaling and digestion (Fricker, 2011). Carboxypeptidases are grouped in two major categories:
serine carboxypeptidases, which contain a serine residue at the active site, and
metallocarboxypeptidases, which contain a zinc atom. The M14 is an important family of
metallocarboxypeptidases with unique physiological functions in humans (Fig. 1). Substrate
specificity exists within the members of this family, with some members exhibiting preference
for basic residues (i.e. CPB2, CPE), acidic residues (i.e. CPO), or non-polar aliphatic/aromatic
residues (i.e. CPA1) (Fricker, 2011).

Figure 1. Phylogeny of the M14 metallocarboxypeptidase family. In red, CPE, CPB2, and CPO.
Contrary to CPO, CPE and CPB2 are well-characterized carboxypeptidases with important
physiological functions such as neuropeptide processing and proteolytic cleavage.
1

A number of studies have successfully described the physiological functions of several
M14 carboxypeptidases. For example, studies by Ji et al. (2017) and Chen et al. (2001) identified
the role of carboxypeptidase E (CPE) in the synthesis of neuropeptides and peptide hormones,
vesicular transport, cellular signaling, and neuroprotection. CPE was originally named
enkephalin convertase after it was found to proteolytically cleave the C-terminal basic amino
acid residues of enkephalin precursors within adrenal chromaffin granules of cattle (Fricker and
Snyder, 1982). In a subsequent study in rats, CPE was found to participate in conjunction with
endoproteases in mid stages of development in rats, where they processed neuropeptide
precursors in the brain as well as proproteins in multiple peripheral locations (Zheng et al.,
1994). Due to its supporting role in proinsulin processing (Harding and Ron, 2002), mutations in
the CPE gene have been directly associated with development of type 2 diabetes in mice and
humans (Fricker et al., 1996; Harding and Ron, 2002). In addition, CPE has been reported to
provide neuronal protection against oxidative stress and cell death (Cong et al., 2017). Moreover,
CPE participates in anterograde transport of synaptic vesicles, which allows for their recycling or
degradation (Ji et al., 2017).
Another M14 member with a significant biological role is thrombin-activatable
procarboxypeptidase B (proCPB2) also known as thrombin-activatable fibrinolysis inhibitor
(TAFI). Following activation by proteolytic cleavage, CPB2 mediates several physiological
functions, namely fibrinolysis, coagulation, and inflammation (Novakovic et al., 2012). Its
inhibitory role in the fibrinolysis cascade is executed through cleavage of the C-terminal lysine
residues from partially degraded fibrin, hence preventing further fibrin degradation by other
enzymes (Leung et al., 2008; Novakovic et al., 2012). In addition, CPB2 is said to work in
conjunction with protein C during injury response at the vascular epithelium: protein C reduces
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the clotting while CPB2 protects the fibrin clot from premature lysis (Leung et al., 2008). A
potential role of CPB2 in inflammation has been proposed after observation of proteolysis of
proinflammatory mediators such as bradykinin, complement C3a and C5a, and thrombin‐cleaved
osteopontin (Novakovic et al., 2012).
Overall, a large number of physiological functions of carboxypeptidases (i.e. CPB2 and
CPE) have been described to date. While some studies continue to further investigate wellcharacterized members of the M14 family, a new interest has emerged to investigate less-known
members. Thus, Lyons and Fricker (2011) recently identified carboxypeptidase O (CPO), a
previously uncharacterized member of the M14 family and closely related to CPB2 (Fig. 1). CPO
was described as a fully functional peptidase that cleaves acidic and polar C-terminal amino
acids of peptides (Burke et al., 2018; Lyons and Fricker, 2011). In addition, CPO was shown to
be expressed on the small intestine, more specifically on the apical surface of enterocytes, and
anchored to the membrane through a glycosylphosphatidylinositol (GPI) modification (Lyons
and Fricker, 2011). Taken together, these findings allude to CPO working extracellularly, likely
cleaving dietary peptides in the intestine (Garcia-Guerrero et al., 2018). Overall, there is a high
possibility of CPO working extracellularly given that 1) GPI anchored proteins are almost
exclusively present on the outer leaflet of the plasma membrane and 2) its location on the apical
surface coincides with that of most GPI-anchored proteins in polarized epithelial cells (Zurzolo
and Simons, 2016).
In addition to the proposed extracellular function cleaving dietary peptides, CPO might
also play an intracellular role. This possibility was suggested after observation of intracellular
expression of CPO in canine-derived epithelial cells where CPO was GPI-anchored to the inner
leaflet of the ER membrane and associated with LDs within this compartment (Burke et al.,
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2018). Overexpression of CPO led to an increase in the number of LDs, as determined by
immunofluorescence microscopy. This finding suggested a physiological function of CPO in the
biogenesis of lipid droplets.
Burke et al. (2018) further hypothesized that CPO could play a role in the formation of
chylomicrons. This suggestion was based on the many similarities between their formation
processes. The most accepted model states that their formation begin due to an accumulation of
neutral lipids (NL) on the ER membrane, grow to form a spherical structure, and ultimately bud
off (Saka and Valdivia, 2012). Conceptually, the most significant difference between these
processes is in the direction of budding. If the nascent droplet buds off outwards to the cytosol, it
will become a cytosolic LD, whereas if it buds off into the ER lumen, the droplet will become a
chylomicron. Given the similarity in the budding processes and the resulting similar composition
– a triglyceride core surrounded by a phospholipid monolayer – it is legitimate to hypothesize
that similar membrane proteins could influence their formation. Thus, CPO might have a role in
formation of both chylomicrons and lipid droplets, namely through cleavage of the C-terminal
residue of a membrane protein that is known to be associated with their formation.
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Figure 2. Model for the formation of lipid droplets from the ER membrane. The accumulation of
neutral lipid (yellow spheres) between the leaflets of the membrane will form a spherical
structure that buds off. If the lipid droplet buds into the lumen, it will later fuse with an apo-B48phospholipid (PL) rich particle and form a chylomicron (CM). CPO (pink) is attached to the
inner leaflet through a GPI anchor (yellow).

2. Digestion
The digestive processes involved in food breakdown and absorption involve a large
number of structures, ranging from organs to accessory glands and include a wide array of
enzymes. Digestion first begins in the mouth and moves through the stomach, aided by
pancreatic secretions, until finally arriving to the small intestine, where chemical digestive
processes continue to further break down dietary disaccharides, polypeptides, and emulsified fats
(Tortora, 2009).

a. Digestion in the brush border
An important part of digestion in the small intestine occurs on the apical surface of
enterocytes, more specifically at the brush border. Although the apical surface has been
considered the hub for final digestion events, recent evidence points to an additional digestion
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mechanism that occurs in the periapical space. Hooton et al. (2015) describe this mechanism,
which lies on the vesicularization of the apical membrane and subsequent movement of the
vesicles into the periapical space. This allows the brush border enzymes, now found on the
membrane of the vesicles, to perform catalysis in the periapical space.
As a key structure in the end stages of digestion, the small intestinal brush border is
characterized by abundant and diverse enzymatic activity. The digestive enzymes present in the
brush border finalize digestion of carbohydrates, proteins and lipids, and can be categorized into
three major groups: disaccharidases /oligosaccharidases, peptidases, and lipases (Hooton et al.,
2015). Carbohydrate digestion is finalized in the brush border by action of disaccharidases such
as sucrase, lactase, and maltase, which break down disaccharides into monosaccharides. In
addition, α-dextrinase acts on small fragments of starch producing glucose (Tortora, 2009).
Likewise, protein digestion is completed by aminopeptidase A, and dipeptidases, resulting in
mostly free amino acids along with few dipeptides and tripeptides (Tobey et al., 1986). In
contrast, lipid digestion can be considered finalized as lipids, which are assembled in spherical
structures called micelles, arrive to the brush border (Tortora, 2009).

b. Absorption in the brush border
When nutrients are broken down into the most simple units (i.e. monosaccharides, fatty
acids, and amino acids), they are able to pass through the enterocytes and eventually reach the
blood or lymph. This process is known as absorption and it entails different forms of transport.
For example, monosaccharides can be transported from the lumen through the apical membrane
in two different ways. Glucose and galactose pass the apical membrane and enter the enterocytes
via secondary active transport with Na+ through Sodium-Dependent glucose transporter 1
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(SGLT1) while fructose is able to enter via facilitated diffusion through Glucose Transporter 5
(Tortora, 2009). These monosaccharides leave through the basolateral membrane via facilitated
diffusion using GLUT2 and are subsequently absorbed into the bloodstream through capillaries.
In the case of amino acids, they may be actively transported into the enterocyte, or they will
enter alongside Na+ via a symporter. As transporters discriminate amongst different classes of
amino acids, a large cohort of transporters have been identified for neutral amino acids (BoAT1),
lysine, arginine, ornithine, and cystine (rBAT, and Bo,+AT), proline and hydroxyproline
(IMINO), aspartic acid and glutamic acid (EAAT3) (Broer, 2008). In contrast, dipeptides and
tripeptides are transported via H+ symporter such as PEPT1 (Hooton et al., 2015). Amino acids,
dipeptides and peptides collectively diffuse out of the enterocyte and enter the blood capillaries.
At the brush border, monoglycerides and free fatty acids (e.g. 2,3-diacylglycerol and 2monoacylglycerol) diffuse out of the micelles into the enterocyte through the apical membrane,
whereas glycerol will freely diffuse in and out of the enterocyte to enter the blood capillary
(Meisenberg and Simmons, 2016). Unlike the aforementioned nutrients, which are simply
transported in and out the enterocytes, free fatty acids undergo a series of chemical modifications
while passing through the enterocytes (Bayly, 2014). Through multiple reactions, free fatty acids
are converted into triglycerides. Triglycerides collectively assemble with phospholipids and
apolipoproteins, thus giving rise to chylomicrons (Tortora, 2009). Due to their considerably large
size (ranging from 200-1,000 mm in diameter) chylomicrons must exit the enterocytes via
exocytosis and are further unable to enter the capillaries (Randolph and Miller, 2014). Instead,
chylomicrons penetrate the adjacent lacteals through large pores located on their tips and are
transported through the lymphatic system to peripheral tissues such as cardiac, adipose, and
muscle (Randolph and Miller, 2014).
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3. Chylomicrons
Over the past couple decades, there has been an increasing interest to study the formation
and metabolism of chylomicrons. This has been mostly due to the recent detection of
chylomicron upregulation in widespread diseases, namely type 2 diabetes and atherosclerosis
(Dash et al., 2015). Clinical conditions involving dyslipidemia such as insulin resistance and type
2 diabetes have been characterized by increased secretion of chylomicrons and apolipoprotein B,
amongst other lipoproteins (Hussain, 2014). This finding has important implications, since
dyslipidemia is one of the greatest risk factors for cardiovascular disease (Dash et al., 2015;
Mooradian, 2009; Xiao et al., 2011), currently labeled as the number one leading cause of death
in the U.S according to the most recent report by the CDC (Kochanek et al., 2019). Additionally,
chylomicron dysregulation further extends to less common diseases, such as genetically
transmitted familial hyperchylomicronemia syndrome (Brahm and Hegele, 2015) and familial
dysbetalipoproteinemia (Koopal et al., 2017).
Chylomicrons are the largest and least dense lipoproteins particles and are composed of a
core of neutral lipids, namely triacylglycerols (85% of the total weight), enclosed by a
phospholipid monolayer (8%) with about 1% of associated apolipoproteins (Demignot et al.,
2014). A form of apolipoprotein B, namely apoB48, is characteristic of chylomicrons and its
presence serves as a marker to differentiate them from other closely-related lipoproteins
(Nakajima et al., 2014). For example, while apoB48 is the main protein in chylomicrons, a
longer form of the protein, apoB100, is the main protein in very-low density lipoproteins
(VLDL) and low-density lipoproteins (Randolph and Miller, 2014). ApoB48 plays a key
structural role in chylomicrons (Xiao, Stahel, & Lewis, 2018) while other apolipoproteins such
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as ApoA-IV assemble on the surface of chylomicrons and play a role in their formation by
determining their size and regulating their secretion (Dash et al., 2015; Xiao et al., 2018).

Figure 3. Schematic illustration of a chylomicron. A phospholipid monolayer surrounds a core
of neutral lipids which is mainly composed of triacylglycerols and sterol esters. Apolipoproteins
apoB48 and apo-AIV located on the surface of the chylomicron play important structural and
regulatory roles, respectively.
While much is known about the physiology and composition of chylomicrons, their
biogenesis is not entirely understood. The most recent model for chylomicron formation suggests
a two-step assembly process. A lipid droplet buds off the inner leaflet of the ER membrane into
the lumen, where it will fuse with a lipidated apoB48-rich particle in a reaction catalyzed by
microsomal triglyceride transfer protein (MTP), eventually giving rise to a pre-chylomicron (Fig.
4; Demignot et al., 2014). After this, the pre-chylomicrons are assembled into pre-chylomicron
transport vesicles (PCTV) and trafficked to the Golgi apparatus (Cartwright and Higgins, 2001;
Demignot et al., 2014).

4. Lipid droplets
Lipid droplets (LDs) and chylomicrons are formed by similar mechanisms. When a lipid
droplet buds off to the ER lumen, it will give rise to a chylomicron; however, if it buds off to the
cytosol, it will become a cytosolic lipid droplet. LDs constitute the major type of cellular
organelle that stores excess neutral lipids namely triacylglycerols and sterol esters (Vevea et al.,
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2015). This storage mechanism is considered protective, since it avoids disruption of membrane
integrity by over-accumulation of neutral lipids (Welte, 2015). In eukaryotes, de novo formation
of LDs occurs due to an accumulation of neutral lipids, on defined regions between the leaflets
of the ER (Roux and Loewith, 2017). The most accepted model proposes that the nascent LD
forms a lens, which grows in size until the LD is fully formed and released (Saka and Valdivia,
2012). LDs that bud off to the cytosol and accumulate on the apical side of the enterocyte, where
they will serve as transient lipid reservoirs (Hussain, 2014).
Nonetheless, LDs are versatile as they have been recently found to have functions beyond
lipid storage. Several studies have identified many LD functions such as storage of vitamins and
molecules involved in cellular signaling, as well as assembly of viruses (Saka and Valdivia,
2012; Welte and Gould, 2017). For example, Welte and Gould (2017) discuss the involvement of
LDs in lipid signaling by means of storage of eicosanoid precursors. Although these precursors,
namely arachidonic acid rich triglycerides, may be obtained through the breakdown of
phospholipids, LDs represent an important additional source. Moreover, LDs constitute major
sites of vitamin A storage (in the form of retinyl esters) with about 80 % of the total reservoir
found in hepatic cells (Welte & Gould, 2017). Cholesteryl esters also stored in the LD core serve
as sources of cholesterol for synthesis of steroid hormones (Kraemer et al., 2013). A well-studied
case of LDs acting as assembly platforms during viral infections is that of hepatitis C. Studies
have shown that localization of the virus core protein on the surface of LDs is necessary for
assembly of new immature viruses (virions) on the host cell (Saka and Valdivia, 2012). Due to
their many physiological roles, LD formation is tightly regulated. Accumulation of lipid droplets
has been associated with major diseases (e.g. type II diabetes, obesity, atherosclerosis, and fatty
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liver disease) which has led to an increasing interest in studying their physiology (Meyers et al.,
2017; Welte and Gould, 2017).
Despite continuing efforts to elucidate the molecular processes behind LD biogenesis,
many questions remain unanswered today (Hussain, 2014; Roux and Loewith, 2017; Wilfling et
al., 2014). Yeast represents a well-studied eukaryote model for lipid metabolism, and its use in
the study of this metabolism is suitable given its high conservation in both humans and yeast
(Karathia et al., 2011). To date, the yeast model has identified many key proteins that participate
in LD formation. For example, Lor1p, a putative homolog of the human lecithin cholesterol
acyltransferase (LCAT), mediates the conversion of diacylglycerol to triacylglycerol (Oelkers et
al., 2000; Roux and Loewith, 2017). The model of lipid formation in yeast is the most detailed
model described to date; however, a number of studies consider this model to be incomplete
since it has failed to describe crucial events in droplet formation, such as the excision of the
nascent LD, thus pointing to a need for further research in this area (Meyers et al., 2017; Roux &
Loewith, 2017; Wilfling et al, 2014).

Figure 4. Schematic illustration of a generic LD. A phospholipid monolayer surrounds a core of
neutral lipids (NL) which is mainly composed of triacylglycerols and sterol esters. While
perilipins (PLIN) and Rab18 proteins are abundant on the LD surface, other LD-associated
proteins (here depicted in green) such as SNARES can be inserted in the phospholipid
monolayer.
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In this study, I investigate a hypothesis initially made by Burke et al. (2018), which
suggested that CPO is involved in the formation of chylomicrons. In addition, I build on previous
work from Burke et al. (2018) by evaluating the association of CPO and LDs in undifferentiated
human colon carcinoma (Caco-2) cells. Here, I show that CPO stably-expressing Caco-2 cells
exhibit CPO association with both LD and apoB, with association in LDs being significantly
dependent upon time elapsed after feeding. A comprehensive analysis of CPO expression data
showed prominent expression in the ileum and modulation of expression in ulcerative colitis and
Crohn’s disease as well as expression in basophils and Peyer’s patches, which suggest promising
implications of CPO in immunity.
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CHAPTER 2

METHODS

1. Compilation of CPO expression data
CPO expression data was obtained from several databases which included RNA
sequencing (RNA-Seq) and microarray data. RNA-Seq data was obtained from publicly
available datasets such as Human Protein Atlas (HPA; www.proteinatlas.org) which allow access
to transcriptomics data, including a compilation of data from prominent datasets such as
Genotype-Tissue Expression (GTEx), HPA, and FANTOM5 CAGE (Pontén et al., 2011).
Additionally, data was gathered from the Bgee website (Bastian et al., 2008), which compiles
RNA-seq data from the Gene Expression Omnibus (GEO; NCBI) and GTEx. Genevestigator, a
powerful transcriptomics analysis tool (Hruz et al., 2008; Zimmermann et al., 2005), was used to
access the mRNASeq_HUMAN_GL-1 platform, thus providing an additional RNA-Seq dataset.
Microarray data was also included in the expression analysis due to its notable prevalence
in transcriptomic profiling. Microarray data, although providing less sensitivity for lowexpression genes, constitutes a reliable choice (Zhao et al., 2014). The microarray data was
retrieved from three platforms. The first one was the Affymetrix Human Genome U133 Plus 2.0
Array, a microarray platform in Genevestigator. The second one was the Bgee website, which
compiled data from the GEO and the ArrayExpress from European Molecular Biology
Laboratory-European Bioinformatics Institute (EMBL-EBI). The third one was the Gene
Expression database of Normal and Tumor Tissues (GENT2; www.gent2.appex.kr) database,
which includes gene expression data from healthy and cancerous tissues. GENT2 compiles
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affymetrix microarray data from U133 Plus 2.0 as well as the U133A platforms (Park et al.,
2019).

2. Site-directed mutagenesis
The goal of site-directed mutagenesis was to introduce a point mutation, E310Q, into
plasmid DNA (pcDNA; Fig. 5). First, custom primers were manually designed. To do this, the
human CPO (hCPO) sequence was translated into its amino acid sequence using the EMBOSS
explorer interface. The amino acid of interest E310 was located and aligned with the
corresponding codon on the forward DNA strand. Overlapping primers were created following
ThermoFisher’s protocol and included the following criteria: 15 base pair complementary
regions with the point mutation located in the middle along with non-overlapping bases at the 3’
end (underlined). The final primer sequences were hCPO-E310Q-F3 5’CGTTTCAGCTGAGGGACAGTGGAAC-3’; hCPO-E310Q-R3 5’CCCTCAGCTGAAACGTATATGAGAAGGG-3’. PCR amplification was used to create the
mutation, and two 50 μL reactions were prepared. Each reaction contained 1.5 μL Platinum
Superfi Polymerase (Thermofisher), 2mM dNTP mix, 30 μL 5x Superfi buffer (Thermofisher), 1
μL template DNA, and 0.5 μM of each primer, and one reaction contained 3% DMSO to enhance
amplification. A BioRad 100 Thermocycler was used with the following program conditions:
98°C (30 s), 98 °C (10 sec), 67.1 °C (10 sec), 72 °C (195 s) repeated for 25 cycles, and final
extension at 72 °C for 5 min. The PCR products were resolved on a 1% agarose gel and
visualized with ethidium bromide/UV. After confirmation of amplification, PCR products were
digested with Dpn1 to remove the parental plasmid DNA, which did not contain the mutations.
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3. Ethanol precipitation
To purify the digested PCR product, ethanol precipitation was performed. The PCR
product (40 μL) was mixed with 0.3 M NaAC (pH 5.2), 250 μL of cold 100% ethanol (-20 °C),
and 50 μL of ddH2O. Following incubation at -80 °C for 30 min, the sample was centrifuged at
21,130 g for 30 min. The precipitate was rinsed with 500 μL of 70% ethanol, centrifuged 21,130
g for 15 min, and resuspended in 10 μL ddH2O.

4. Bacterial transformation
DH5α competent E.coli cells were transferred from the -80 °C freezer and allowed to
thaw on ice for 15 min. Two controls, a positive and a negative, were prepared by addition of 25
μL DH5α cells to 5 μL pcDNA [hCPO] (1 ng/μL) and 5 μL ddH2O respectively. Additionally,
two experimental samples, one with 5 μL digested PCR product and one with 5 μL of the
digested + purified PCR product were prepared by addition of 50 μL DH5α cells. The samples
were gently mixed, incubated on ice for 30 min, and heat shocked for 40 s at 42 °C. Following a
5 min incubation on ice, 200 μL of sterile Luria Broth (LB) were added and mixed by stirring
with the pipet tip. The samples were incubated at 37°C for 60 min and then spread on
LB/ampicillin plates, which were incubated at 37 °C overnight. The plates were inspected for
colony growth 16 h following plating.

5.

Plasmid preparation by NID method
Colonies were randomly selected from both the plates: three colonies from the plate with

digested DNA and three colonies from the plate with digested + purified DNA. In culture tubes,
2 mL of sterile LB broth and 2 μL ampicillin were mixed. The colonies were individually
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scooped from the plates with a flamed pipet tip and resuspended in the mixture contained within
the culture tube. The tubes were later placed in a shaking incubator at 37 °C for 20 h.
A larger working stock of pcDNA-hCPO E310Q was produced by a large-scale bacterial
transformation. The volumes of reagents and pcDNA (see above) were reduced by 5-fold, while
bacterial cultures were grown in culture tubes with about 5-fold the volume of LB broth and
ampicillin. After 12 h of incubation at 37°C, 1 mL of the culture was transferred to a flask
containing 50-fold volume of LB broth and ampicillin and grown for 8 additional hours.
The contents of the culture tubes were transferred to 2 mL tubes and centrifuged at
21,130 g for 30 s. The pellets were resuspended in 150 μL of extraction buffer (5% sucrose, 50
mM EDTA, 50 mM Tris pH 8.0, 0.75 M NH4Cl, 0.5% Triton X-100, 100 μg/mL lysozyme, 25
μg/mL RNAase A) and incubated at 65 °C for 5 min. Following centrifugation (10 min at 21,130
g), the pellet was removed with a sterile toothpick and mixed with 120 μL of isopropanol by
vortexing. The mixture was centrifuged at 4,602 g and the supernatant was subsequently
discarded. To the tube, added 500 μL 70% ethanol was added and it was centrifuged at 21,130 g
for 10 min. In order to remove any supernatant left, the bulk of it was pipetted out and then the
pellet was allowed to air dry for 10 min. The pellet was resuspended in 50 μL of EB buffer.
In the large-scale NID plasmid prep, the contents of the culture tubes were transferred to
50 mL tubes and centrifuged (3,000 g for 5 min at 0 °C). The pellet was resuspended in 5 mL of
extraction buffer and the tube was incubated in a 65 °C water bath for 8 min. Following
centrifugation (19,000 g for 30 min at 0 °C), the supernatant was transferred to a new tube,
mixed with 7 mL of isopropanol. After the sample was centrifuged (19,000 g for 15 min at 0 °C),
the pellet was resuspended in 1.5 mL of 70% ethanol and centrifuged at 15,000 rpm for 5 min. In
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order to remove any supernatant left, the bulk of it was pipetted out and then the pellet was
allowed to air dry for 10 min. The pellet was resuspended in 400 μL of EB buffer.

6. DNA quantification
DNA isolated from each of the six E.coli colonies was visualized on a 1% agarose gel.
Each sample loaded contained 1 μL template DNA, 2 μL 6x loading dye and 7 μL ddH2O. An
image of the gel taken with AlphaImager imaging system was analyzed using ImageJ (NIH).
This image processing program allowed quantification of the DNA by comparison to the marker
lane (Tridye 1kb).
Spectrophotometry was used to calculate the quantity and purity of the pcDNA-hCPO
E310Q, known as the ratio of absorbance at 260 nm over the absorbance at 280 nm
(A260/A280). In a UV compatible cuvette, mixed 2 μL template DNA and 198 μL ddH2O were
mixed and absorbance measured at 260 nm and 280 nm.

7. Sanger sequencing
In accordance with Genescript’s requirements (NJ, USA), only those DNA samples with
optimal yields were selected and prepared for sequencing. Preparation was done by addition of 5
μL of T7 primer (10 μM) to 10 μL of template DNA. Sanger sequencing and subsequent
alignment to the hCPO sequence (Accession: NM_173077.3) using BLAST allowed
confirmation of the presence of the target mutation (Fig. 5).
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Figure 5. Site-directed mutagenesis is used to create the mutant pcDNA-hCPO E310Q. A set of
custom partially overlapping primers with 3’ overhangs (blue arrows) containing single point
mutations (red) were used to amplify the plasmid. Transformation into competent cells allows to
produce large quantities of the primer, which are subsequently purified. Presence of mutation is
confirmed via Sanger sequencing

8. Maintenance of Caco-2 cell line
Caco-2 were grown in an incubator set to 37°C and 5% CO2 and maintained in
Dulbecco’s Modified Eagle Medium supplemented with 10% Fetal Bovine Serum (Sigma
Aldrich) and 1% Penicillin/Streptomycin (Sigma Aldrich). The cells were passaged at 1:5 or 1:10
(vol/vol) when ≅ 80 % confluency was reached. To passage the cells, the media was removed
and the cells were washed twice with Dulbecco’s modified Phosphate Buffered Saline (PBS;
Sigma) and trypsinized (Trypsin-EDTA 1x; Sigma) for 6 min in the incubator. The cells were
subsequently resuspended in fresh complete medium and seeded at desired density. Medium was
regularly changed every 48 h.

9. Transfection of Caco-2 cells
Caco-2 cells were seeded in a 6-well plate at a density of 1.5 x105/well with 2 mL of
complete medium 24 h before transfection. Once at room temperature, the reagents were mixed
in a sterile 1.5 mL tube as follows: first, 200 μL of serum-free DMEM were mixed with 3 μg
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total plasmid DNA (Fig. 6). Second, the diluted DNA was mixed with 9 μL Polyethylenimine
(25kD linear; Polysciences, cat# 23966-2). After incubation at room temperature for 15 min, the
mixture was added to the cells and the plate was mixed 6-8 times. Cells were incubated at 37°C
and 5% CO2 for 48 h.

10. Selection of stable transfectants
Post-transfection, the cells were counted on a hemocytometer and subcultured at the desired
density in 100 mm dishes. Selection of stable transfectants began 24 h after with addition of
Geneticin (G418) at 0.8 mg/mL to the medium (Fig. 6). Medium was changed and supplemented
with G418 three times a week for three weeks. Resistant clones were observed under a brightfield microscope and those exhibiting healthy morphologies were marked for further expansion.
To isolate the individual clones, the dishes were washed twice with 5 mL of Dulbecco’s PBS and
a cloning disc previously soaked on trypsin for 15 min was placed directly on top of each
selected clone. After incubation at 37°C for 5-6 min, the discs were transferred to a 24-well plate
containing 0.5 mL medium and mixed 6-8 times. Medium was changed 2-3 times a week. As
G418-resistant clones reached moderate confluences (50-70%), they were transferred to 6-well
plates, where they were maintained with addition of fresh medium three times a week. A
population of stable transfectants were maintained in 100 mm dishes with complete medium
supplemented with 0.8 mg/mL G418.

11. Preparation of cell extracts for western blotting analysis
G418-resistant clones of stably transfected cells were trypsinized in 1 mL of trypsin and
resuspended in 1 mL of complete medium. Resuspended cells were transferred to a 2 mL tube
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and kept on ice, and 0.1 mL were used for cell counting. The resuspended cells were centrifuged
for 1 min at 5,000 g. After removing the supernatant, 2 mL of PBS were added and the tubes
were vortexed and centrifuged for an additional minute. The volume of cold lysis buffer (150
mM NaCl, 20 mM Tris pH 7.5-8.0, 1% Triton X-100, 2 mM EDTA, 1 mM PMSF) added to the
pellet was proportional to the number of cells in the extracts. Samples with the highest cell count
were resuspended in 300-400 μL of buffer, while 70-100 μL of buffer was used for samples with
the lowest cell counts. The mixtures were passed through a 22 G ½ needle 8-10 times. After
centrifugation at 21,130 g for 2 min, the supernatant (containing the cell extracts) was transferred
to a new tube and stored at -20°C overnight.

12. Western blotting
Samples for western blotting by mixing 20 μL cell extracts with 5 μL 5x sample buffer
(0.375 M Tris pH 6.8, 12% SDS, 60% glycerol, 0.6 M DTT, 0.06% bromophenol blue). The
samples were heated for 3 min at 95 °C and 15-20 μL were loaded onto a 10% SDS-PAGE gel
and ran at 160V for 65 min. The gel was subsequently incubated in 1X transfer buffer (25 mM
Tris Base, 192 mM glycine, 10% MeOH) and transferred for 60 min at 100 V onto a
nitrocellulose membrane, then blocked in a solution of 5% non-fat milk in TBST (Tris-buffered
saline, 0.1% Tween 20). Incubation of the nitrocellulose membrane was done with rabbit RP3CPO (Triple Point Biologics; 1:5000 dilution) as the primary antibody and HRP conjugated antiRabbit IgG (Cell Signaling Technology; 1:2000 dilution) the secondary antibody. Nitrocellulose
was treated with Lumi-GLO chemiluminescent reagent (Cell Signaling Technology) for 1 min
and exposed to an X-ray film in a cassette, followed by manual development.
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Figure 6. Illustration of transfection and selection protocols. Plasmid DNA containing WT or
E310Q CPO (in red) is added to the cell cultures (pictured: 100mm culture dish). Cell cultures
are treated with geneticin (G418) 2-3 times a week. A population of resistant clones is
transferred to 24-well plates and expanded. Cell extracts from clones that were successfully
expanded are analyzed for CPO expression via western blotting.

13. Immunofluorescence
Coverslips were incubated with Poly-D-lysine in PBS (1 mg/mL) for 1 h, washed with
sterile H2O, and dried under UV light for 1h. Caco-2 cells from a pooled polyclonal culture
containing hCPO WT transfectants were seeded at 1.5 x105 cells/well in 6-well plates containing
poly-D-lysine coated coverslips. When cells reached 60-80% confluency, they were washed
three times with PBS, fixed in 4% paraformaldehyde for 10 min at room temperature, and then
washed three times for 5 min on the rocker. The cells were permeabilized in 0.1% Triton X-100
in PBS for 15 min, washed, and blocked with 5% bovine serum albumin in PBS for 35 min.
Primary antibodies RP3-CPO (Triple Point Biologics, cat.# MAB41241-100; 1:1000 dilution) or
human Apolipoprotein B (R&D Systems, 1:25 dilution) were diluted in 5% bovine serum
albumin in PBS and added directly onto the coverslip and incubated for one hour. After washing
three times with PBS, the cells were incubated with secondary antibodies anti-mouse Alexa
Fluor 488 and/or anti-rabbit Alexa Fluor 555 (Cell Signaling Technology, 1:1000 dilutions).
Coverslips were washed three times and then mounted with 12 μL of aqueous mounting medium
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(PBS containing 1 mg/mL p-phenylenediamine hydrochloride and 1 μg/ml DAPI). To stain lipid
droplets, 4 μL BODIPY (Invitrogen) was added to the coverslip during the penultimate washing
step and incubated on the rocker for 13 min. The slides were allowed to dry in a cool, dark place
overnight and were later stored at 4°C.
Images of thirteen fields of view containing at least one CPO-expressing cell were
captured with a fluorescence microscope. To evaluate association, % values (LD:CPO or
apoB:CPO) were normalized using the arcsin transformation and subsequently analyzed by a
one-way ANOVA.

14. Carboxypeptidase Assay
Twenty microliters of HEK293T cell extracts were incubated with 100 μL 0.5mM Fa-EE
carboxypeptidase substrate in a 96 well plate and their A340 was measured at 24°C every min
for a total of 30 min.
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CHAPTER 3

RESULTS

1. Analysis of CPO expression
In order to better understand the potential biological role of CPO, an in-depth analysis of
data from several gene expression databases was performed. Investigating the levels of
expression across organs and tissues can potentially shed some light on the biological function of
this protein. Thus, a comprehensive collection of CPO expression data is an appropriate
approach to accomplish this.
Protein expression is commonly similar to RNA expression which can be quantified
using transcriptomic techniques (Wang et al., 2009). These transcriptomic techniques present a
high-throughput, highly sensitive sequencing method that allows quantitative assessment of the
expression of a gene in a given tissue or cell line (McGettigan, 2013). This is achieved by
measuring the RNA transcript abundance found for a given protein-coding gene. For the
purpose of the expression analysis in this study, RNA sequencing (RNA-Seq) and microarray
data were compiled.

a.

CPO expression in the small intestine
CPO exhibits its highest levels of expression in the small intestine, as found in RNA-Seq

and microarray databases. The consensus expression found in proteinatlas.org, which includes
data from HPA, GTEx and FANTOM 5, collectively denote the small intestine as the tissue with
highest expression in humans (Fig. 7A-C). In addition, HPA indicates that CPO expression is
tissue enriched, as it is at least 4x greater than in any other tissue. More specifically, microarray
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data from the Affymetrix Human Genome U133 Plus 2.0 Array platform revealed that CPO is
overwhelmingly expressed in the ileum (Fig. 8B). The affymetrix microarray data was found to
closely match the data found in the mRNASeq_HUMAN_GL-1 platform, both referring to
location and relative levels of expression (Fig. 8A). Notably, in the mRNASeq platform the
aforementioned ileal epithelium is referred to as the terminal ileal epithelium. High levels of
expression were detected in the ileal epithelium, also known as mucosa. RNA-Seq data from
Bgee further suggests that within the ileal mucosa, lymphoid structures known as Peyer’s
patches, are the anatomical entity with the highest relative CPO expression (Fig. 7D).

b. CPO expression in other tissues
In addition to the small intestine, CPO exhibits varying levels of expression in other
tissues including male reproductive tissues, brain, adrenal, and thyroid (Figs. 7,8). According to
the HPA and FANTOM 5 databases, the epididymis is the tissue with the second highest CPO
expression (Fig. 7A,C). This claim is supported by the Affymetrix Human Genome U133 Plus
2.0 Array platform, which names two regions with medium expression levels, namely the
epididymal cauda and corpus (Fig. 8B). Although the mRNASeq platform fails to include the
epididymis, it mentions another male reproductive structure, the testis, with medium-low
expression (Fig. 8A).
The brain exhibits widely spread CPO expression with varying levels of expression. For
example, the Affymetrix Human Genome U133 Plus 2.0 Array platform indicates that medium
expression levels are found in a variety of neural structures. Within the medium expression level
range, the cingulate cortex neuron had the highest expression, followed by the hippocampus
pyramidal neuron, basal ganglia, entorhinal cortex large stellate neuron, and the hypothalamus
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(Fig. 8B). While the Affymetrix U133 platform suggests medium expression in multiple brain
tissues, RNA-Seq data suggests low to background level expression in most of those tissues (Fig.
8A).
RNA-Seq data from Bgee and mRNASeq_HUMAN_GL-1 report that the caudate
nucleus and caudate-putamen complex, respectively, as the sites with highest expression in the
brain; nonetheless, the expression levels in both structures appears to be modest (Figs. 7D, 8A).
Further, the mRNASeq_HUMAN_GL-1 platform reports medium expression in the
hippocampus, which contrasts with the background level expression detected by RNA-Seq from
GTEx (Fig. 8A, 7B, respectively). GTEx and FANTOM 5 do not report regional specificity nor
specific distribution of CPO in the human brain. Nonetheless, both databases report low
expression in the ganglia while GTEx also reports expression in the pituitary gland (Fig. 7A,C).
Taken together, the data points to an overall low presence in the brain.
Low levels of CPO expression are seen in adrenal tissues. The adrenal gland cortex
presents a moderate expression score, as determined by RNA-Seq databases from Bgee (Fig.
7D). Expression in the adrenal gland is also reported in the mRNASeq_HUMAN_GL-1,
Affymetrix Human Genome U133 Plus 2.0 Array, and GTEx platforms (Fig. 8A,B; Fig. 7A).
While overall expression in the adrenal gland is moderate, it appears to be slightly greater in the
fetal stage than in adulthood (Fig. 8A,B). Nonetheless, it is important to note that none of the
aforementioned platforms report expression in both fetal and adult, thus making it challenging to
establish a fair comparison across platforms. Additionally, low expression is detected in the
thyroid gland, as reported in and GTEx, HPA, Bgee, and Affymetrix Human Genome U133 Plus
2.0 Array, (Fig.7 A, B, D; Fig. 8B).
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Figure 7. CPO is largely expressed in the small intestine and has low expression in a number of
other tissues. CPO expression levels were determined by RNA-Seq data from HPA (A), GTEx
(B), FANTOM 5 (C) datasets and both RNA-Seq/Affymetrix from the BGEE website (D). The
small intestine is collectively reported as the tissue with highest CPO expression (A-D), and
expression in other tissues is considerably lower than in the small intestine (A,B,C). Expression
scores from Bgee have been normalized (0-100) from expression call values across genes and
conditions within the species, with scores below ~80 arguably considered as moderate
expression (D). Modified from http:// proteinatlas.org and http://bgee.org.

26

A

B

Figure 8. CPO is expressed in blood cells, male reproductive, brain, and adrenal tissues, with
highest expression in the ileum mucosa and ileal epithelial cells. Gene expression is reported as
absolute levels in log2 scale, with low, medium, and high ranges specific to the
mRNASeq_HUMAN_GL-1 platform (A) and the Affymetrix Human Genome U133 Plus 2.0 Array
platform (B). In the affymetrix microarray platform (B), the mean value of the ileal mucosa
“13.92” (shown as log2) equals “35,075” in linear scale, which compares to “7.25” (shown as
log2) and “231.77” in linear scale according to the mRNASeq platform (A). Data is modified
from Genevestigator.
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c. CPO expression in the Blood
The blood was found to be the third highest tissue displaying significant CPO expression.
mRNA expression data from the HPA database revealed enrichment of CPO expression in
granulocytes, specifically the basophils (Fig. 9). Similarly, the mRNASeq_HUMAN_GL-1
platform also reports medium levels of CPO expression in low density basophils (Fig. 8A). In
contrast, the Affymetrix Human Genome U133 Plus 2.0 Array platform reports a wider variety
of blood cells with CPO expression ranging in the medium levels, with bone marrow plasma
cells at the highest, then CD4 t-large granular lymphocyte, followed by T-cells, neutrophils, and
eosinophils (Fig. 8B). A small, almost negligible level of expression in eosinophils is also found
in the HPA database (Fig. 9).
Interestingly, granulocytes are white blood cells, known to play a crucial role in
immunity. More specifically, basophils are involved in inflammatory responses such as allergic
reactions (Wedemeyer et al., 2000). Thus, CPO expression in the basophils alludes to a potential
role of CPO in immunity. Moreover, the expression in Peyer’s patches, known to play a role in
immunity by creation of B-lymphocytes also alludes to a link between CPO and immunity.

Figure 9. CPO expression in blood cells. Out of 29 total cell types analyzed by RNA-Seq, only
three showed CPO expression, with basophils exhibiting the highest levels of expression at 8.9
pTPM. Modified from http://proteinatlas.org.

28

d. CPO expression in cell lines
While CPO is expressed across a variety of cell lines, its highest levels of expression are
detected in cancer derived cell lines. RNA-seq data from the HPA database reports four cell lines
where CPO is moderately expressed, and three of which are human cancer cell lines (Fig. 10A).
These cancer cell lines are NB-4, from the bone marrow, ASC diff, from sarcoma, BEWO, from
the brain, and the non-cancerous telomerase immortalized cell line hTCEpi, originating from the
cornea. The mRNASeq_HUMAN_GL-1 platform cites four different cell lines with medium
expression, with HD-iPS4-HTT at the highest followed by NCl-446, SNU-349, and WA09 (Fig.
10B). HD-iPS4-HTT constitutes induced pluripotent stem cells from Huntington’s disease
patient, while WA09 is a human embryonic stem cell line. The remaining two, NCl-446 and
SNU-349 are cancer cell lines, from the lung and renal carcinoma respectively. A lung cancer
metastatic cell line is reported to have high levels of CPO expression, according to the
Affymetrix Human Genome U133 Plus 2.0 Array platform (Fig. 10C). Additionally, medium
CPO expression levels are reported in embryonic stem cell WA07, mammary epithelial cell line
76N-RHOA, and bone marrow metastatic cancer cell line Rh30 (Fig. 10C).
Because CPO has prominent expression in the small intestine and basophils, we sought to
investigate this expression in cell culture models, namely Caco-2, which has an intestinal
phenotype, and a human basophil cell line, KU812. Both cell lines presented low to no
expression according to mRNASeq_HUMAN_GL-1 and Affymetrix Human Genome U133 Plus
2.0 Array platforms. Overall, Caco-2 has a more consistent record of expression, with mediumlow expression reported by the Affymetrix Human Genome U133 Plus 2.0 Array platform and
low expression reported by the mRNASeq_HUMAN_GL-1 platform (Fig. 10B,C, respectively).
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In turn, KU812 has medium CPO expression according to the affymetrix microarray platform,
whereas the mRNA-seq platform notes no expression (Fig. 10C; 10B, respectively).

Figure 10. A diverse number of cell lines, mostly cancer derived, have moderate levels of CPO
expression. RNA-seq data from HPA (A) shows three cancer cell lines with important CPO
expression (in pTPM), NB-4, ASC diff and BEWO, while the mRNASeq_HUMAN_GL-1 platform
(B) includes two, NCI-H446 and WA09 with medium expression (in absolute levels in log2 scale).
The Affymetrix Human Genome U133 Plus 2.0 Array (C) is the only platform to report a cell line
(CL-H446) with high CPO expression. Data modified from Genevestigator and
http://proteinatlas.org.

e.

CPO expression and associated pathology
A number of pathological disorders characterized by chronic inflammation of the

digestive tract have shown abnormal CPO expression levels. These pathological disorders are
considered subtypes of the inflammatory bowel disease (IBD) and include Crohn's disease and
ulcerative colitis (Baumgart and Sandborn, 2012). Since they share many symptoms, these two
pathologies are mainly differentiated by their localizations. Crohn's disease can develop
anywhere along the digestive tract, while ulcerative colitis is confined to the colon (Baumgart
and Sandborn, 2012; Head and Jurenka, 2003). Clinical data retrieved from Genevestigator
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mRNA-Seq (mRNASeq_HUMAN_GL-1) and affymetrix microarray (Human Genome U133
Plus 2.0 Array) platforms revealed two main sites with high CPO expression where such
pathological conditions have been reported.
The first site was identified as the ileal mucosa and was characterized by the highest CPO
expression (Fig. 11A, 12A). A study by Arijs et al. (2009; Genevestigator ID (G-ID): HS-00598)
assessed expression in healthy patients and Crohn’s disease patients who were receiving
Infliximab treatment. The results of the study suggest a pattern of decreased expression in
Crohn’s disease patients (Fig. 11B).
Similarly, the ileal epithelium, which was ranked second highest in expression in the
affymetrix microarray platform, reported high-medium expression in all patients (n = 6)
diagnosed with Crohn's disease (Funke et al., 2009; G-ID: HS-01050; Fig. 11C). These levels of
expression in diseased patients appear to be less than those detected in healthy patients,
coinciding with the presumed trend observed by Arijs et al. (2009; G-ID: HS-00598) in the ileal
mucosa. Furthermore, a large study conducted by Howell et al. (2018; G-ID: HS-03228) reported
expression ranging from high to medium in 17 patients with IBD (n = 17) (Fig. 12B). Upon
analysis of the individual cases, it was found that all the patients with ulcerative colitis (n = 7)
exhibited higher expression levels than those with Crohn's disease (n = 10; Fig. 12C). Likewise,
most Crohn's patients exhibited decreased expression versus healthy individuals (n = 6).
Additionally, ulcerative colitis appears to modulate CPO expression, as seen by a
differential modulation in ileal tissue. For example, one study (Haberman et al., 2014; G-ID: HS01562) reported CPO expression was modestly downregulated in ileal tissue of young patients
(aged 0-10 years old) with ulcerative colitis (Fold Change (FC): -1.63; p < 0.001) (Fig. 12C). In
the same study, older diseased patients (10-17 years old) showed increased expression than
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younger patients (FC: +1.61; p < 0.001), indicating that CPO expression specifically in the ileum
of diseased patients may be age dependent.
In contrast, CPO is more drastically regulated in Crohn’s disease. One study by Peck et
al. (2015; G-ID: HS-01505) found a very large upregulation of the CPO gene in colon tissue of
patients with bowel stricture (B2) and penetrating (B3) Crohn's disease (FC: 12.15 and 4.28,
respectively; p < 0.001) (Fig. 12C). Conversely, CPO was significantly downregulated in the
ileum of diseased pediatric patients, as reported in study G-ID: HS-01562 (Haberman et al.,
2014). More specifically, the downregulation was greater in patients aged 10-17 (FC: -4.45; p <
0.001) than in patients aged 0-10 (FC: -3.57; p < 0.001).
Although CPO is modulated in both IBD conditions, ulcerative colitis and Crohn’s
disease, the data indicates a much more evident relationship between CPO and Crohn’s disease.
When comparing CPO expression in both pathologies, a study (G-ID: HS-01562; Haberman et
al., 2014) found that CPO is significantly more downregulated in ileal tissue in Crohn’s disease
versus ulcerative colitis (Fig. 12C). In fact, this difference is greater in Crohn’s patients who
exhibit deep ulcers (FC: -4.51; p < 0.001) than in those with a clinically affected colon (FC: 2.13; p < 0.001) (Fig. 12C). Downregulation in Crohn’s disease was more moderate in younger
patients (FC: -1.38; p = 0.033; Fig. 12C).
In addition, moderate CPO expression has been reported in several pathologies, including
cancer. In an analysis of expression across 72 paired tissues, the GENT2 database showed that
CPO was significantly overexpressed in cancerous small intestinal and blood tissue (p = 0.026
and p < 0.001, respectively) (Fig. 13). Colon carcinoma and lymphoma, although based on a very
small sample size (n = 2), exhibit high CPO expression (Fig. 11A). Other pathologies with
medium expression levels were the monoclonal gammopathy of undetermined
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significance (MGUS) and multiple myeloma. Furthermore, a study on adrenal cortical carcinoma
(G-ID: HS-01616; Zheng et al., 2016) found a moderate downregulation in patients on stage IV
compared to those on stage I (FC: -2.2; p < 0.001). (Fig. 12C).

Figure 11. CPO expression data from the Affymetrix Human Genome U133 Plus 2.0 Array
platform. The platform identifies high levels of CPO expression the ileal mucosa and ileal
epithelium cells, with a trend indicating decreased expression in Crohn’s disease patients.
Microarray data from Genevestigator includes CPO expression levels across 1,066
anatomy/cancer entries, and identifies the ileum as the primary site of expression (A). Two
studies, G-IDs: HS-01050 and HS-00598, found decreased expression in the ileal epithelium
cells (B) and ileal mucosa (C) of patients with Crohn’s disease. The experimental treatment in
study HS-00598 consisted of a single Infliximab dose (5mg/kg body weight) (C). Values shown
are absolute expression levels in log2 scale. Modified from Genevestigator.
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Figure 12. CPO expression data from the mRNASeq_HUMAN_GL-1 platform. This RNA-Seq
platform reports CPO expression levels across 624 anatomy/cancer entries, and identifies the
ileum as the primary site of expression (A). A study (G-ID: HS-03228) reported decreased levels
of expression in IBD patients, with ulcerative colitis patients exhibiting higher expression than
Crohn’s (B). Values shown are absolute expression levels (TPM) in log2 scale. C. CPO
expression is differentially modulated in IBD patients, with older patients (aged 10-17)
presenting stronger regulations than younger patients (aged 0-10). CPO expression is regulated
more strongly in Crohn’s disease patients than in ulcerative colitis patients. Log2-ratio
represents the difference between the average log2 expression for experimental and control
samples. Modified from Genevestigator.

Figure 13. CPO is overexpressed in cancerous small intestinal and blood tissues. In an analysis
of expression across 72 healthy and cancerous “paired” tissues, the GENT2 database reported a
significantly increased log2 fold-change in small intestine (p = 0.026) and blood tissue (p <
0.001). Modified from http://gent2.appex.kr/gent2.
34

2. Creation of the hCPO E310Q mutant
Unlike other members of the M14 family, CPO is expressed as a constitutively active
enzyme, as it does not need to undergo proteolytic cleavage to be activated (Garcia-Guerrero et
al., 2018). Thus, to control for enzyme activity and protein expression, it is useful to employ an
inactive CPO mutant as a means of comparison against the fully active (WT) CPO. This may be
achieved through mutagenesis of a key catalytic residue, namely E310, which will effectively
suppress the catalytic ability of CPO. An hCPO E310Q mutant was created with the ultimate
goal of comparing the association of CPO with lipid droplets (LDs) and apoB48 in WT and
E310Q CPO expressing Caco-2 cells. Differences in association would be considered in light of
CPO activity (in WT) or lack thereof (in E310Q).

a. Why E310Q?
The selected mutation was on a key catalytic residue, E310. To assess any potential steric
strain in the hCPO E310Q mutant, a 3-D model of the molecule was visualized using PyMOL
(Fig. 14A). A close-up on the catalytic residue area revealed minimal change in structure due to
the similarity of the two amino acids, glutamic acid (E) and glutamine (Q; Fig. 14B). Essentially,
these two residues only differ in the terminal side chain, where E contains a -COOH group and Q
has a -CONH2. Thus, modeling of the point mutation E310Q in hCPO verified that the steric
hindrance produced by the mutagenesis was negligible.
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Figure 14. The E310Q mutation substitutes a key catalytic residue in hCPO without contributing
steric hindrance. A. Three-dimensional structure of hCPO in its monomeric form (PDB: 5RMV).
E310, a key catalytic residue, is shown in magenta. Zinc cofactor is depicted as a yellow sphere.
B. A close-up of the 3-D hCPO model showing a key catalytic residue E310 (top) and its mutated
form Q310 (bottom). While the E310Q mutation does not add any steric hindrance, it effectively
inhibits hCPO catalytic activity.

b. Site-directed mutagenesis
A PCR-based mutagenesis procedure was used to perform site-directed mutagenesis.
Amplification of hCPO DNA using mutagenic primers was visualized via gel electrophoresis
(Fig. 15). Bands of similar sizes were seen in +DMSO and -DMSO PCR products, indicating
that addition of DMSO did not enhance amplification.

Figure 15. HCPO DNA was successfully amplified and resolved using gel electrophoresis. PCR
products with and without DMSO exhibited similar bands.

Prior to performing ethanol precipitation, the PCR products (± DMSO) were mixed with
each other resulting in two products that contained about half of the +DMSO PCR reaction and
half of the -DMSO. Both 50/50 products were digested by addition of 2.5% Dpn1. Ethanol
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precipitation was performed only on one of the samples to purify it by concentrating the DNA
and remove unwanted substances (Soares et al., 2012). Because of the complexity of the
technique and the risk of losing DNA, it was decided that it would be appropriate to perform this
only on one sample. Subsequent assessment of bacterial growth confirmed that the ethanol
precipitation step was unnecessary, as colonies containing digested DNA were larger and more
abundant than those containing ethanol purified DNA (n = 16 and n = 14, respectively).
After transformation, plasmid from E.coli colonies was purified and visualized on a 1%
agarose gel (Fig. 16A). DNA quantification showed that only colonies 2 and 3 had optimal
amounts of plasmid required for sequencing.
Sanger sequencing was used to confirm the presence of the novel mutation (C→G) in
both samples. Presence of the E310Q mutation (*) was confirmed using sequence alignment
against the hCPO WT (BLAST). The best mutant was selected on the basis of presence of the
mutation and overall DNA quality, as determined by the base calls in the chromatogram (Fig.
16B).

Figure 16. Confirmation of the mutagenesis in bacterial cells. A. After transformation, pcDNA
from three E. coli colonies (1-3) was purified and visualized on a 1% agarose gel. B. Presence of
the E310Q mutation (*) was confirmed using sequence alignment against the hCPO WT
(BLAST). The missense mutation results in the coding of glutamine (Q) instead of glutamic acid
(E). The best mutant was selected on the basis of presence of the mutation and overall DNA
quality, as determined by the base calls in the chromatogram. In blue, reverse compliment of
codon coding for E; in red, reverse compliment of codon coding for Q.

37

c. Testing the expression and catalytic activity of the hCPO E310Q mutant
i.

Western blotting

To determine expression of the hCPO E310Q mutant, HEK293T cells were transiently
transfected with pcDNA-hCPO E310Q. HEK293T cells were also transfected with empty vector
pcDNA3.1(-) and pcDNA-hCPO WT, which were used as negative and positive controls,
respectively. Each transfection was performed in duplicate. The cell extracts were subsequently
collected and analyzed via western blotting. Analysis via western blotting revealed that the
E310Q mutant had similar hCPO expression as the WT hCPO (Fig. 17A).
ii.

Carboxypeptidase Assay

Two carboxypeptidase (CP) assays were run independently. Successful proteolytic
cleavage of the substrate by CPO can be measured by a decrease in absorbance at 340 nm (Fig.
17B). The average activity of the E310Q mutant (0.051 milliUnits/min) was significantly smaller
than that of the WT (1.59 milliUnits/min) as determined by Student’s t-test (p < 0.005). In
contrast, E310Q and empty vector had similar activity, suggesting that hCPO E310Q lacked
catalytic activity.

Figure 17. Analysis of hCPO E310Q expression and catalytic activity in mammalian cells. A.
Extracts from HEK293T cells transiently transfected with empty vector (-), pcDNA-hCPO WT
and pcDNA-hCPO E310Q were analyzed via western blotting. The E310Q mutant had similar
hCPO expression as the WT. B. To measure enzymatic activity, HEK293T cell extracts were
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incubated with 0.5mM Fa-EE substrate and their A340 was measured at 24°C every min for a
total of 30 min. Values shown are averages from two separate carboxypeptidase (CP) assays.

3.

Cell transfection and selection with hCPO WT and hCPO E310Q
Caco-2 cells are considered a good model to study intestinal physiology, as they mimic

molecular and physiological characteristics of the small intestinal epithelium (Natoli et al.,
2012). Although the Caco-2 cell line is an optimal choice for this study, its endogenous
expression of CPO is low and thus insufficient to accurately assess enzyme activity (Fig. 10B,C).
Therefore, to be able to study the activity of CPO in Caco-2 cells, it was necessary to produce a
hCPO stably expressing cell line.

a. Control experiments
Prior to performing the transfection with pcDNA-hCPO WT and pcDNA-hCPO E310Q,
several control and optimization experiments were conducted. First, to control for transfection
efficiency, Caco-2 cells were transiently and stably transfected with a fluorescent plasmid. Also,
the selection protocol was optimized by experimentally determining optimal G418 concentration.
Finally, an attempt to optimize the transfection protocol included the testing of two transfection
reagents, PEI and FuGENE6.

i.

Determining effective G418 concentration

In order to serve as a good selective agent, G148 must be used at an optimal
concentration to induce cell lethality before cells reach confluency. Thus, G418 concentration as
well as seeding cell density are key factors to consider when optimizing the selection protocol.
Thus, an experiment was designed where Caco-2 cells were seeded at 43,000 cells/ml in a 6-well
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plate. G418 was added at three different concentrations: 0.6 mg/mL, 1mg/mL, and 4mg/mL. One
well that received no G418 supplementation was used as a control. Medium was changed and
supplemented with fresh G418 every 48 h. Cell toxicity was visually assessed at 48 h, 72 h, and
92 h following the first G418 addition.
Visual assessment of cell toxicity revealed that the minimum lethal concentration was
between 0.6-1mg/mL. Approximately 48 h after the first G418 addition, cell toxicity was similar
at 0.6 mg/mL and 1mg/mL of G418, whereas it was much more severe at 4 mg/mL, as seen by a
considerably larger number of floating cells. At 92 h, the confluence at 1 mg/mL was half of that
observed at 0.6 mg/mL. In contrast, the confluency at 4 mg/mL G418 was extremely low (10 %)
with large cohorts of dead cells as compared to the control. These results suggest that a
concentration of 4 mg/mL is not optimal, since large amounts of dead cells will correlate to
secretion of undesired substances that may in turn affect the resistant cells leading to their death.
Treatment with 0.6 mg/mL and 1 mg/mL G418 successfully killed non-resistant cells within 92 h
without massive cell death. Thus, optimal lethal concentration required for optimal selection of
resistant clones lies in the 0.6-1mg/mL range.

ii.

Transient transfection using fluorescent plasmids

To assess the efficiency of transfecting Caco-2 cells using the PEI transfection reagent,
Caco-2 cells were transiently transfected with various fluorescently tagged plasmids. Three
plasmids with fluorescent tags were used for transfection: pEGFP-N2, pcDNA-GFP-CAAX, and
pcDNA-mCherry-CAAX. The cells were observed under a fluorescent microscope 48 h post
transfection. Quantification of transfection efficiency was calculated by dividing the number of
fluorescent cells per field of view by that area (0.35 mm2) and multiplying by surface area of the
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6-well plate (9.6 cm2). The total number of transfected cells was reported as the average of three
fields of view. While all three transfections were successful, quantification of the observed
fluorescence revealed varying transfection efficiencies (Fig. 18). The pEGFP-N2 had the highest
transfection efficiency at ≅ 21,000/250,000 transfected cells per well, while pcDNA-mCherryCAAX had the lowest with ≅ 15,500/250,000. This suggests a transfection efficiency of 5-10%
for this system.

Figure 18. Caco-2 cells transiently transfected with fluorescently tagged plasmids. Plasmids
pEGFP-N2 (A), pcDNA-GFP-CAAX (B), and pcDNA-mCherry-CAAX (C) were used as
transfection markers to assess the transfection efficiency in Caco-2 cells. Fluorescent cells in
three fields of view were manually counted and the average was used to estimate the transfection
efficiency for each of the plasmids. Images show fluorescent cells, n = 8 in (A), n = 4 in (B), and
n = 3 in (C). With a total cell number of about 250,000 cells per 9.6cm2 , 21,000 cells were
transfected with pEGFP-N2 ,20,800 with pcDNA-GFP-CAAX, and 15,500 with pcDNA-mCherryCAAX.

iii.

Stable transfection using a fluorescent plasmid

Caco-2 cells were seeded in a 6-well plate at a density of 3 x105/mL and subsequently
transfected with 3 μg total pEGFP-N2 pcDNA 24 h after (see Chapter 2, section 9). 48 h posttransfection, the cells were subcultured at ≃ 54,500 cells/mL in 100 mm dishes with fresh
medium. After selection with G418 (see above), cells were observed under a fluorescent
microscope and three resistant clones presenting uniform, bright fluorescence were selected by
marking their location on the plate. Two isolated resistant clones were grown to ≃70 %
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confluency in a 24-well plate at 37°C and 5% CO2, and expanded into 60 mm dishes.
Fluorescence was observed three weeks post-selection, suggesting that the transfection and
selection protocols were optimal for producing stable transfectants (Fig. 19).

Figure 19. Caco-2 cells stably transfected with a fluorescently tagged plasmid, pEGFP-N2. Here
pictured are four fluorescent cells in a field of view. Two stably transfected clones were isolated
and visualized with a fluorescent microscope to confirm fluorescence three weeks post-selection
with G418.

iv.

Semi-transient transfection with pcDNA-hCPO WT and hCPO E310Q

Caco-2 cells were transfected with 3 μg total pcDNA-hCPO WT and pcDNA-hCPO
E310Q (see Chapter 2, section 9). 48 h post-transfection, the cells were subcultured at ≃ 10,600
cells/mL for WT and 19,500 cells/mL for E310Q in 100 mm dishes. The cells were grown to
confluency at 37°C and 5% CO2 for seven days, and media was changed every other day. After
trypsinization and resuspension, a small volume of the cells was set aside to be counted. The
remainder of the cells (2,012,800 cells WT and 3,180,800 cells E310Q) were harvested and lysed
in lysis buffer (see Chapter 2, section 11). Cell extracts from transient hCPO WT and E310Q
transfectants were analyzed via western botting with rabbit RP3-CPO as the primary antibody
and HRP conjugated anti-Rabbit IgG as the secondary antibody (see Chapter 2, section 12). After
a 55 min exposure, both transfectants exhibited bands at the expected product size for CPO
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(about 42.5 kDa; Fig. 20). Nonetheless, the presence of a shadow in an empty lane adjacent to
the mutant sample “Caco-2 hCPO E310Q” argues to consider the possibility of spillover.

Figure 20. Caco-2 cells transiently transfected with pcDNA-hCPO WT and pcDNA-hCPO
E310Q. Transient hCPO expression was assessed seven days post-transfection. Cell extracts of
Caco-2 hCPO WT and E310Q transfectants were harvested, lysed, and analyzed via western
blotting. Cell extracts from HEK293T cells transfected with pcDNA-hCPO WT were used as a
positive control.

v.

Optimization of transfection with PEI and FuGENE6

Since the semi-transient transfection results did not confidently indicate a successful
transfection, it was decided to revisit the transfection protocol to investigate the efficiency of the
transfection reagent, PEI. Given that transfection efficiency is largely determined by the ratio of
the transfection reagent to the DNA, I attempted to optimize the transfection protocol by testing
the transfection efficiency using multiple PEI:DNA ratios. To do this, Caco-2 cells were seeded
at 3x105 cells/well in 6-well plates and transfected with WT hCPO pcDNA at varying PEI:DNA
ratios (μL PEI, and μg for DNA, respectively): 1:3, 3:3, 9:3, 15:3, 20:3, 1:1, 3:1, 9:1, 15:1, 20:1.
Transfection with fluorescent plasmid pEGFP-N2 at a 9:3 ratio was used as a control.
Cell extracts were harvested, lysed, and analyzed via western blotting (see Chapter 2,
sections 11,12). None of the cell extracts showed expression (not shown). While these results
may be suggestive of some form of human error in the experiment, the control sample showed
abundant fluorescence, thus ruling out that possibility. An additional attempt to optimize the
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transfection efficiency with CPO involved the use of a high efficiency transfection reagent,
FuGENE 6. The transfection was done according to the manufacturer’s protocol (Roche) and
pEGFP-N2 was used as a control. Assessment of the control sample post-transfection with
FuGENE6 revealed minimal fluorescence, and it was concluded that this fluorescence was less
than that observed in the previous optimization experiment with PEI. Thus, the low levels of
fluorescence in the control sample suggested low transfection efficiency with FuGENE6. In
contrast, high levels of fluorescence demonstrated that transfection with pEGFP-N2 using PEI
was successful; however, low hCPO expression, possibly below the western blot detection limits,
prevented confirmation of transfection. Thus, failure to detect hCPO expression via western
blotting did not necessarily indicate failure of the transfection, but rather suggested low hCPO
expression levels.

b.

Isolation of stable transfectants expressing hCPO WT and hCPO E310Q

Caco-2 cells were seeded at 0.8 x105 cells/well in a 6-well plate and subsequently
transfected with plasmids expressing hCPO WT, hCPO E310Q, and pcDNA3.1(-) empty vector
(see Chapter 2, section 9). 48 h post-transfection, cells were passaged at 1:2 (vol/vol) and seeded
into 100 mm dishes. Twelve hCPO WT resistant clones, thirteen hCPO E310Q, and nine empty
vector resistant clones were grown in 24-well plates using the aforementioned protocol (see
Chapter 2, section 10). Cell extracts were centrifuged at 5,000 g for 1 min and the pellet was
resuspended in 1x sample buffer. Volumes of sample buffer added ranged from 100 to 300 μL
and were directly proportional to the size of the pellet. Cell extracts from resistant clones (four
hCPO WT, eight hCPO E310Q, and three empty vector) were analyzed by western blotting (see
Chapter 2, section 12). Western blotting analysis of four hCPO WT and eight E310Q resistant
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clones showed that all lacked CPO expression (not shown). A closer inspection of the western
blotting results revealed that some resistant clones presented a single band of faint intensity at
around 65 kDa, which corresponded to bovine serum albumin (BSA) protein.
Resistant clones with BSA expression indicated protein presence in the sample, which
argued for potential presence of hCPO. If hCPO expression was presumably too low to be
detectable via western blotting, then further expanding the clones would increase the number of
hCPO expressing cells thus allowing detection of expression. Thus, resistant clones with BSA
expression (four hCPO WT and four hCPO E310Q) were transferred from their respective 6-well
plates to 100 mm dishes for further expansion. After reaching 70-100% confluency, the resistant
clones were harvested and lysed in lysis buffer (see Chapter 2, section 11). Eight resistant clones
(four hCPO WT and four hCPO E310Q) showed no CPO expression, as determined by western
blotting analysis (Fig. 21A)
In a second attempt to isolate stably expressing hCPO WT and E310Q transfectants,
Caco-2 cells were seeded at 3x105 cells/well in 6-well plate and transfected with WT, E310Q and
3.1 pcDNA (see above). Resistant clones with healthy morphologies (nineteen hCPO WT,
nineteen hCPO E310Q, and three empty vector) were harvested from the 100 mm dishes and
expanded in 24-well plates. Twenty-one resistant clones (eleven hCPO WT and ten hCPO
E310Q) showed no CPO expression, as determined by western blotting analysis (Fig. 21B).
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Figure 21. Resistant clones from stably expressing hCPO WT and hCPO E310Q transfectants
showed no CPO expression. Caco-2 cells were transfected and subsequently selected with G418
for three weeks. WT (n = 15) and E310Q (n = 14) resistant clones were harvested and analyzed
via western blotting to test for hCPO expression. Extracts from HEK293T cells transfected with
plasmids expressing hCPO, either WT (A,B) or L230K (A), and two empty vector clones Cl.3, 1
(-) (B) were used as controls.

4. Immunocytochemistry
Previous research has shown an association between CPO and LDs in canine kidney cells
and has further suggested the possibility of an association between CPO and chylomicrons. In
this study, we investigated the association between CPO, LDs, and chylomicrons in Caco-2 cells,
which are known to closely mimic intestinal physiology and anatomy. To test the potential
association between CPO and LDs or chylomicrons, immunocytochemistry was performed using
a culture of Caco-2 cells that contained pooled hCPO WT stable transfectants. Notably, the usage
of a Caco-2 cell line that stably expressed both hCPO WT and E310Q would have been more
optimal than a pooled culture containing a small number of hCPO WT expressing cells.
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Nonetheless, transitioning to using this pooled culture was deemed as the next logical step after
numerous unsuccessful attempts to create hCPO WT and E310Q stable transfectants.
In order to compare any differences in association in differentiated and undifferentiated
cells, a batch of Caco-2 cells from the pooled culture was differentiated. Caco-2 cells were
differentiated into an epithelial monolayer of mature enterocytes by growing them in 6-well
plates with coated coverslips (see Chapter 2, section 13) for 21 days. Prior to being analyzed via
immunocytochemistry, undifferentiated and differentiated cells were fixed at 12 h and 48 h postfeeding. For immunocytochemistry, the samples were divided into two groups: LD/CPO and
apoB/CPO. Following permeabilization and blocking (see above), cells in the LD/CPO group
were labeled with RP3-CPO primary antibody, whereas cells in the apoB/CPO group were
labeled with both RP3-CPO and Apolipoprotein B primary antibodies. Similarly, secondary
antibody anti-rabbit Alexa Fluor 555 was used for the LD/CPO and the same antibody in
conjunction with anti-mouse Alexa Fluor 488 was used for the apoB/CPO group.
Observation of the slides under the fluorescent microscope revealed that the number CPO
expressing cells was low (not shown). This reduced number of transfected cells presented a
challenge to assess association of CPO with LDs and chylomicrons. In addition, differentiated
cells presented blurry staining, possibly as a result of the thickness of the cell monolayer (not
shown). In light of these results, it was decided to transiently transfect the pooled culture of
undifferentiated Caco-2 to increase the number of CPO expressing cells. Transiently transfected
cells from the pooled Caco-2 cell culture were fixed at 6 h, 12 h, and 24 h post-feeding and
analyzed via immunocytochemistry (Figs. 22,23).
Thirteen fields of view of each experimental condition were analyzed, with at least one
hCPO transfected cell in each field of view (range 1-4, x̄: 1.6). LDs, apoB, and CPO puncta were
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manually counted, and the association was computed by calculating how many of the total LD or
apoB molecules were seen associated with CPO (expressed as % of total LDs or apoB).
Similarly, association was computed in non-transfected cells to evaluate baseline background
staining.
CPO was associated with both LDs and apoB, with the highest % association found 12 h
post-feeding (29.8% and 30.4%, respectively; Figs. 22A; 23A). Both LD and apoB presented the
lowest association with CPO at 6 h (17.9% and 22.8%, respectively), reaching a maximum at 12
h, and later slightly decreasing at 24 h (26.3% and 29.1%, respectively; Figs. 22B; 23B). CPOexpressing cells exhibited defined, bright red puncta, which appeared as fuzzier and dimmer
background spots in non-expressing cells. Non-transfected cells consistently exhibited lower
association values, suggesting that the computed CPO, LD, and apoB puncta in transfected cells
likely were not background staining (not shown). However, we note that the distribution of CPO
and apoB puncta in Fig. 23A does not appear to correlate with the association values reported in
Fig. 23B. Thus, we express a limited level of confidence regarding the apoB:CPO association
reported herein.
LD:CPO association was found to be significantly different at 6, 12, and 24 h (F = 4.27, p
= 0.02), whereas apoB:CPO association was found to be non-significant between the time points
(F = 1.8, p = 0.179).
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Figure 22. CPO associated with lipid droplets in transiently transfected Caco-2 cells. A pooled
culture of stable CPO transfectants was transiently transfected and fixed at 6, 12, and 24 h post
feeding. A. The cells were immunostained with CPO antibody and BODIPY to observe lipid
droplets. CPO-expressing cells exhibited defined, bright red puncta (A, cell on the left of upper
left panel), which appeared as fuzzier and dimmer background spots in non-expressing cells (A,
cell on the right of upper left panel). B. The LD:CPO association (%LDs) was determined using
thirteen fields of view, and was found to be the highest at the 12 h mark. The LD:CPO
association was significantly different at 6 h, 12 h, and 24, h (p = 0.02), by one-way ANOVA.
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Figure 23. CPO associated with apoB, a marker for chylomicrons, in transiently transfected
Caco-2 cells. A pooled culture of stable CPO transfectants was transiently transfected and fixed
at 6, 12, and 24 h post feeding. A. The cells were immunostained with CPO and apoB antibodies.
B. The apoB:CPO association (%apoB) was determined using thirteen fields of view, and was
found to be the highest at the 12 h mark. ApoB:CPO association did not significantly vary
amongst the three time points.
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CHAPTER 4

DISCUSSION

1. Evaluation of expression data
Protein expression data collected from several RNA-Seq and microarray databases (see
Chapter 3) collectively identify the small intestine, more specifically the ileum epithelium, as the
site of highest CPO expression in the human body. In this case, RNA-Seq and microarray data
indicate the same site of maximum expression; however, these expression scores vary greatly
from each other. More importantly, microarray data appears to show rather high levels of
background expression. This becomes evident when comparing the expression scores for the
anatomical structure with the lowest expression in the Affymetrix Human Genome U133 Plus
2.0 Array microarray platform and the mRNASeq_HUMAN_GL-1 platform. As it would be
expected, the lowest expression reported in the mRNASeq platform is 0, which corresponds to
the spinal cord motor neuron. In contrast, the lowest mean score in the affymetrix microarray
platform is 179, which corresponds to the myeloid progenitor cell.
For many years following the creation of the first Affymetrix GeneChip® technology in
1994, microarrays have continued to play an essential role in research (Lenoir and Giannella,
2006). However, microarrays are being gradually replaced by newer, more complex sequencing
technologies such as RNA-Seq. This transitioning to RNA-Seq can be understood in light of the
numerous disadvantages associated with microarrays such as limited detection range, crosshybridization, and high background noise (Song et al., 2015; Wang et al., 2009; Zhao et al.,
2014). My findings show high levels of background noise in data collected from Bgee and
Affymetrix Human Genome U133 Plus 2.0 Array platform. While it is important to identify
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background noise, it may not drastically affect the interpretation of expression data with high
expression levels. In contrast, interpretation of medium and low expression data can be easily
affected by background noise, thus leading to an overestimation of expression. The present study
found medium CPO expression in a myriad of anatomical entities such as the epididymal cauda
and adrenal gland (Figs. 7D; 8B). In light of the large background noise (i.e. 231 in Affymetrix
Human Genome U133 Plus 2.0), a corrected expression would place the aforementioned entities
in the low expression range. This correction of the microarray expression data would then match
the values of similar structures reported by RNA-Seq (Figs. 7A-C; 8A).
Additionally, analysis of CPO expression in IBD pathologies revealed several patterns
that could provide insight into the physiological function of CPO. For example, Crohn's disease
presents significant upregulation in colon tissue and downregulation in ileal tissue. Interestingly,
the upregulation in colon tissue, reported to be upwards of 12-fold (p < 0.001; Fig. 12C), is the
largest upregulation of CPO across all pathologies shown in the Genevestigator database (Peck et
al., 2015). Preliminarily, this finding can raise questions regarding the underlaying mechanisms
of Crohn's disease. Such mechanisms can presumably lead to overexpression of CPO in the
colon, or alternatively, rely on a transport and subsequent relocation of CPO from ileal
epithelium to the colon. Although it would be exciting to investigate these possibilities, low
expression of CPO in the colon (1.5 pTPM in HPA, 1 pTPM in GTEx, and 0.4 pTPM in
FANTOM 5; Fig. 7A-C, respectively) seems to undermine the relevance of such a large fold
change.
The findings of Haberman et al. (2014) point to modulation of CPO expression in the
ileum with promising implications. The study, which included Crohn's disease patients aged 0-17
(Satsangi et al., 2006) showed a significant downregulation of CPO in ileal tissue of (p < 0.001;
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Fig. 12C). Since the ileum is the site of highest CPO expression (Figs. 7, 8), a downregulation of
about 4-fold is considered prominent, and further suggestive of a function of CPO in this disease.
Crohn's disease is characterized by chronic intestinal inflammation emerging at an
interface of genetic susceptibility, environmental factors, imbalance of enteric bacteria, and a
strong immune response led by T-cells (Sartor, 2006; Shanahan, 2002). This pathology presents
a variety of phenotypes, which have been classified into age (A1- 3), location (L1- 4) and
behavior (B1- 3) categories according to the Montreal guidelines (Satsangi et al., 2006). Thia et
al. (2010) investigated the clinical characteristics of 306 patients who had been diagnosed with
Crohn's disease. They showed that 56% of diagnoses corresponded to patients aged 17 – 40 (A2),
and only 11% corresponded to patients aged 0-16 (A1). Moreover, the study showed that the
terminal ileum was the most commonly affected site, accounting for 45% of the total. While the
disease may shift amongst behavior phenotypes (B1-3), it reportedly maintains a constant
location (Baumgart and Sandborn, 2012). This would suggest that the findings of Haberman et
al. (2014), although pertaining to a younger patient cohort, may likely apply to older patients as
well.
Although a series of pathologies are expressed at varying levels across phenotypes
(Antoni et al., 2014), a common feature in the pathogenesis of Crohn's disease is a defective
intestinal mucosal barrier. The mucosal barrier represents the first line of immunological defense
in the small intestine, so the emergence of disease associated perturbations directly affects
intestinal function and integrity (Sartor, 2006). Such defects include, but are not restricted to,
decreased presence of mucus biofilm, alterations in expression of intercellular junction proteins,
increased transepithelial permeability linked to migration of leukocytes, and decreased
production of antimicrobial peptides (Antoni et al., 2014; Baumgart and Sandborn, 2012).
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Ultimately, these factors have been shown to produce epithelial apoptosis in Crohn's disease
patients (Antoni et al., 2014; Zeissig et al., 2007). Thus, destruction of mucosal barrier
epithelium, with appearance of gaps and microerosions (Antoni et al., 2014), would explain the
downregulation of CPO in the ileal epithelium reported by Haberman et al. (2014).
Additionally, RNA-Seq data from Bgee showed high expression of CPO in Peyer’s
patches (Fig. 7D), which are intimately associated with the immunological response of Crohn’s
disease. These structures represent the first-line of adaptive immunological defense in the
intestine (Kogan and von Andrian, 2008) and have significant presence in the ileum (Shah and
Misra, 2011). In an effort to assess the presence of Peyer’s patches in the small intestine, a
preliminary study by Cornes (1965) set out to quantify these organs across selected age groups
ranging from gestational period to adolescence. The study showed that in adolescents, the
number of patches ranged from 100 to 239, but most importantly, that the number and size of the
patches increased with age (Cornes, 1965). Thus, an increased abundance of Peyer’s patches in
later developmental stages could imply a similar pattern in CPO expression. Interestingly, RNASeq data from Bgee shows highest expression in early adulthood (25 – 44 years old), and
moderate expression in late adulthood, with no reports of earlier developmental stages. Taken
together, these reports may indicate that Peyer’s patches and CPO expression could follow a
bell-shaped curve; increasing from childhood until early adulthood, and subsequently decreasing
after. A modulation of CPO expression resulting from variation in abundance of Peyer’s patches
could suggest that CPO activity is relevant in these organs, possibly aiding in their proliferation.
Another potential role of CPO in immunity is suggested by significant expression in basophils
(Fig. 9). Although basophils are the least abundant granulocytes, they are known to play
important roles in adaptive immunity, namely allergic reactions (Min et al., 2004). Future studies
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should further investigate these promising associations to gain more insight into the
physiological function of CPO.

2. Evaluation of Caco-2 transfection attempts
We set out to investigate the function of CPO in a stably-expressing Caco-2 cell model.
Two separate attempts were made to stably transfect and isolate G418 resistant hCPO WT and
E310Q clones; however, we found no CPO expression amongst the analyzed clones (n = 38; Fig.
21). Analysis of CPO expression following a semi-transient transfection presumably showed
expression in both hCPO WT and E310Q samples (Fig. 20). Nonetheless, this possibility was
refuted after close inspection of the X-ray film, which showed a faint shadow on an empty lane,
thus hinting at the possibility of spillover.
These results prompted us to question if the inability to produce stable transfectants was
related to CPO or rather cell-line specific. Lyons and Fricker (2011) reported creation of an
epithelial Madin-Darby canine kidney (MDCK) cell line stably expressing CPO. MDCK cells
can be easily transfected (Di et al., 2011) unlike Caco-2 cells, which are well-known for being
difficult to transfect (Cerda et al., 2015). Other studies have successfully stably transfected Caco2 cells with a myriad of proteins including cyclooxygenase-2 (Tsujii et al., 1997), insulin-like
growth factor I (IGF-I) receptors (Di Popolo et al., 2000), and integrin-initiated extracellular
signal-regulated (ERK) kinase (Sanders and Basson, 2000). Notably, these studies used high-end
transfection reagents (Lipofectamine and Lipofectamine PLUS), which contrasts with the costeffective reagent, namely PEI, used in this study. To our knowledge, we are the first study to
report use of PEI to produce transiently and stably expressing Caco-2 cells. The reliability of the
PEI reagent was demonstrated in separate transfection experiments with GFP (Figs. 18,19).
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Given the abundant evidence showing that Caco-2 cells can be stably transfected, we
wondered whether the inability to produce stable transfectants was CPO-specific. More
specifically, we hypothesized that CPO overexpression in Caco-2 cells could be cytotoxic. Due
to the low endogenous CPO presence in Caco-2 cells (Fig. 10), an increased expression posttransfection could be toxic to the cells. Reeves et al. (2002) reported numerous cases of
cytotoxicity linked to protein expression when attempting to create stably expressing cell lines.
In this regard, Andréll and Tate (2013) argue against constitutive expression of membrane
proteins when seeking to create stably expressing mammalian cell lines. Protein overexpression
induces cellular stress, further leading to loss of expression over time and delayed cell growth.
To address these issues, Andréll and Tate (2013) propose the use of an inducible system such as
tetracycline, which enables inducible expression of the protein for short time periods. In our
study, CPO was presumably constitutively expressed for 42-52 days, from time of transfection
until harvesting of the cells. It is possible that CPO was expressed upon transfection and that
factors such as extended length of the G418 selection (40-50 days), excessive stress and toxicity
could have resulted in low protein expression at the time of analysis.

3. CPO association with LDs and apoB in Caco-2 cells
Using a culture with pooled stably expressing Caco-2 transfectants, we show that CPO
associated with LDs and apoB; nonetheless, we acknowledge a discrepancy between the
quantified apoB:CPO association, which ranges from 22-30%, and the association shown in the
immunocytochemistry images (Fig. 23A), which appears lower. CPO association with LDs was
found to be dependent on the time elapsed post-feeding, as seen by lowest association at 6 h
(18%) and highest at 24 h (30%), followed by a small decrease at 48 h (26%) (p = 0.02; Fig.
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22B). A similar, yet not statistically significant association pattern was shown by apoB (Fig.
23B).
The observed association between CPO and LDs expand on findings previously reported
by Burke et al. (2018), which showed this association in differentiated MDCK cells. Burke et al.
(2018) found an association that, similarly to ours, varied upon time elapsed from the last
feeding until fixation; however, two notable differences were found when comparing association
patterns. First, we report an increase in association from 6 h and 12 h time points (12%) which is
6-fold higher than that reported by Burke et al. (2018). Secondly, the decrease in association
from 12 h and 48 h time points (4%) represents a fourth of that reported in Burke et al. (2018).
Despite use of similar methods by Burke et al. (2018), the variability between association levels
could be due to differences in quantification techniques. Overall, the association of CPO with
LDs confirms results previously reported by Burke et al. (2018) in a more optimal intestinal
model, and further strengthens the hypothesis that CPO plays a role in lipid formation in
enterocytes.
We also report association of CPO with apoB in stably expressing undifferentiated Caco2 cells; nonetheless, we express a limited level of confidence in these results due to an apparent
discrepancy between the immunocytochemistry images and the quantification data. Although not
statistically significant, our results point to a similar pattern of association to that of LDs at 6 h,
12 h, and 48 h time points (Fig. 23B). A rather weak fluorescence of apoB detected through
immunocytochemistry (Fig. 23A) suggested lower abundance than initially expected. Thus, it
appeared that low detection could correlate to low apoB secretion in undifferentiated Caco-2
cells. Early work by Reisher et al. (1993) confirmed secretion of apoB in undifferentiated Caco-2
cells, an event previously thought to occur only after differentiation. In a subsequent study,
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Luchoomun et al. (1997) stably expressed the apoB48 isoform in Caco-2 cells and found that
over 50% of the apoB48 was degraded intracellularly.
Since the present study sought to investigate the association between CPO and
chylomicrons, we wondered if levels of apoB48, a well-known chylomicron biomarker
(Nakajima et al., 2014), could predict the presence of chylomicrons in undifferentiated Caco-2
cells. The findings of Luchoomun et al. (1997) indicate that undifferentiated Caco-2 cells can
secrete chylomicron-like particles if subject to conditions that mimic a postprandial state, which
can be achieved by supplementation of media with oleic acid. This evidence suggests that
apoB48 metabolism, and to a lesser extent chylomicrons, can be studied in undifferentiated
Caco-2 cells. Nonetheless, it appears that the use of differentiated Caco-2 cells may be more
appropriate, as demonstrated by their use in a large amount of studies on chylomicron and
apoB48 metabolism (Jiao et al., 1990; Nauli et al., 2014; van Greevenbroek et al., 1996).
In addition, it is uncertain what percentage of the apoB detected in the
immunocytochemistry assay pertained to apoB48 and/or apoB100, since the primary antibody
appears to detect both isoforms of the apolipoprotein. Therefore, future studies should consider
the use of western blotting analysis to resolve both apoB isoforms, or alternatively, the use of an
apoB48-specific antibody. In addition, it is suggested to mimic postprandial state conditions in
differentiated cells by use of oleic acid and/or lecithin to further enhance chylomicron production
(Nauli et al., 2014). Overall, the evidence suggests that the conditions used in this study were not
ideal for an adequate study of chylomicron metabolism.
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4. Conclusion
In conclusion, the results of the present study show that CPO associates with LDs in
undifferentiated Caco-2 cells and that this association is dependent on time elapsed post-feeding.
Furthermore, this study used an intestinal model to expand on the findings of Burke et al. (2018),
thus strengthening the hypothesis that CPO plays an intracellular role in the formation of lipid
droplets in enterocytes. Future studies aiming to analyze intracellular CPO substrates and
binding partners could provide insight into the potential physiological function of CPO. We also
report that CPO associates with apoB in undifferentiated Caco-2 cells; however, we express a
limited level of confidence in these results since the immunocytochemistry images presumably
suggest lower association levels than those reported in the quantification data. Further, we
acknowledge that the parameters used to study chylomicron metabolism were not optimal and
hence should be revised ahead of future studies. Further work should investigate the association
of CPO and chylomicrons in differentiated Caco-2 cells in the presence and absence of oleic
acid. Lastly, a comprehensive analysis of CPO expression data revealed modulation of CPO
expression in Crohn’s disease as well as expression in basophils and Peyer’s patches, all of
which could be indicative of a function of CPO in immunity.
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